{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+IR+tablets", "query": { "intervention": "Metformin IR tablets" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Metformin+IR+tablets&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T10:05:27.784Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01463774", "title": "A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Treatment A: Canagliflozin tablet", "type": "DRUG" }, { "name": "Treatment A: Metformin IR tablets", "type": "DRUG" }, { "name": "Treatment B: Canagliflozin/metformin fixed dose combination tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 74, "start_date": "2011-09", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2012-11-21", "last_synced_at": "2026-09-03T10:05:27.784Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01463774" }, { "nct_id": "NCT02206607", "title": "Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "PF-04937319 IR MST", "type": "DRUG" }, { "name": "PF-04937319 MR 1", "type": "DRUG" }, { "name": "PF-04937319 MR 2", "type": "DRUG" }, { "name": "PF-04937319 MR 3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 39, "start_date": "2014-09", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-03-04", "last_synced_at": "2026-09-03T10:05:27.784Z", "location_count": 2, "location_summary": "High Point, North Carolina • San Antonio, Texas", "locations": [ { "city": "High Point", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206607" }, { "nct_id": "NCT01508195", "title": "A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Canagliflozin tablets", "type": "DRUG" }, { "name": "Metformin IR tablets", "type": "DRUG" }, { "name": "Canagliflozin/metformin IR FDC tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 64, "start_date": "2012-01", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2013-01-31", "last_synced_at": "2026-09-03T10:05:27.784Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01508195" }, { "nct_id": "NCT01525225", "title": "Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Metformin immediate release (IR)", "type": "DRUG" }, { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Metformin IR", "type": "DRUG" }, { "name": "Saxagliptin/Metformin XR FDC", "type": "DRUG" }, { "name": "Metformin XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 4, "start_date": "2012-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2015-06-22", "last_synced_at": "2026-09-03T10:05:27.784Z", "location_count": 7, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525225" }, { "nct_id": "NCT02220218", "title": "Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Metformin IR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 2, "start_date": "2014-08", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2014-11-19", "last_synced_at": "2026-09-03T10:05:27.784Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02220218" }, { "nct_id": "NCT00885378", "title": "Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Saxagliptin plus metformin IR", "type": "DRUG" }, { "name": "Placebo plus metformin IR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 166, "start_date": "2009-05", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2015-06-01", "last_synced_at": "2026-09-03T10:05:27.784Z", "location_count": 25, "location_summary": "Concord, California • Fountain Valley, California • Lomita, California + 22 more", "locations": [ { "city": "Concord", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Altamonte Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00885378" }, { "nct_id": "NCT01619059", "title": "Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Metformin IR", "type": "DRUG" }, { "name": "Placebo matching with Saxagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 315, "start_date": "2012-06", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-04-22", "last_synced_at": "2026-09-03T10:05:27.784Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01619059" }, { "nct_id": "NCT01508182", "title": "A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Canagliflozin tablets", "type": "DRUG" }, { "name": "Metformin IR tablets", "type": "DRUG" }, { "name": "Canagliflozin/metformin IR FDC tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 64, "start_date": "2012-01", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-09-03T10:05:27.784Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01508182" }, { "nct_id": "NCT02526524", "title": "Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Met DR", "type": "DRUG" }, { "name": "Met IR", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elcelyx Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 571, "start_date": "2015-09", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2018-04-27", "last_synced_at": "2026-09-03T10:05:27.784Z", "location_count": 134, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Tuscumbia, Alabama + 107 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02526524" }, { "nct_id": "NCT04885530", "title": "ACTIV-6: COVID-19 Study of Repurposed Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Ivermectin", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Fluticasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Susanna Naggie, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 10956, "start_date": "2021-06-08", "completion_date": "2024-04-29", "has_results": true, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-09-03T10:05:27.784Z", "location_count": 110, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04885530" } ] }